Grundläggande statistik
| CIK | 1344413 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Alexza Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| July 15, 2016 |
15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 000-51820 ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as s |
|
| July 5, 2016 |
Alexza Pharmaceuticals S-8 POS S-8 POS As filed with the Securities and Exchange Commission on July 5, 2016 Registration No. |
|
| July 5, 2016 |
Alexza Pharmaceuticals S-8 POS S-8 POS 1 d217084ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on July 5, 2016 Registration No. 333-207585 Registration No. 333-205860 Registration No. 333-202760 Registration No. 333-194803 Registration No. 333-189011 Registration No. 333-186249 Registration No. 333-180048 Registration No. 333-176173 Registration No. 333-171604 Registration No. 333-164843 Registration No |
|
| July 5, 2016 |
Alexza Pharmaceuticals S-8 POS As filed with the Securities and Exchange Commission on July 5, 2016 Registration No. |
|
| July 5, 2016 |
Alexza Pharmaceuticals S-8 POS As filed with the Securities and Exchange Commission on July 5, 2016 Registration No. |
|
| July 5, 2016 |
Alexza Pharmaceuticals S-8 POS S-8 POS 1 d217084ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on July 5, 2016 Registration No. 333-207585 Registration No. 333-205860 Registration No. 333-202760 Registration No. 333-194803 Registration No. 333-189011 Registration No. 333-186249 Registration No. 333-180048 Registration No. 333-176173 Registration No. 333-171604 Registration No. 333-164843 Registration No |
|
| July 5, 2016 |
Alexza Pharmaceuticals S-8 POS S-8 POS 1 d217084ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on July 5, 2016 Registration No. 333-207585 Registration No. 333-205860 Registration No. 333-202760 Registration No. 333-194803 Registration No. 333-189011 Registration No. 333-186249 Registration No. 333-180048 Registration No. 333-176173 Registration No. 333-171604 Registration No. 333-164843 Registration No |
|
| July 5, 2016 |
Alexza Pharmaceuticals S-8 POS S-8 POS As filed with the Securities and Exchange Commission on July 5, 2016 Registration No. |
|
| July 5, 2016 |
Alexza Pharmaceuticals S-8 POS S-8 POS As filed with the Securities and Exchange Commission on July 5, 2016 Registration No. |
|
| July 5, 2016 |
Alexza Pharmaceuticals S-8 POS S-8 POS As filed with the Securities and Exchange Commission on July 5, 2016 Registration No. |
|
| July 5, 2016 |
Alexza Pharmaceuticals S-8 POS S-8 POS As filed with the Securities and Exchange Commission on July 5, 2016 Registration No. |
|
| July 5, 2016 |
Alexza Pharmaceuticals S-8 POS S-8 POS As filed with the Securities and Exchange Commission on July 5, 2016 Registration No. |
|
| July 5, 2016 |
Alexza Pharmaceuticals S-8 POS As filed with the Securities and Exchange Commission on July 5, 2016 Registration No. |
|
| July 5, 2016 |
Alexza Pharmaceuticals S-8 POS S-8 POS 1 d217084ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on July 5, 2016 Registration No. 333-207585 Registration No. 333-205860 Registration No. 333-202760 Registration No. 333-194803 Registration No. 333-189011 Registration No. 333-186249 Registration No. 333-180048 Registration No. 333-176173 Registration No. 333-171604 Registration No. 333-164843 Registration No |
|
| July 5, 2016 |
Alexza Pharmaceuticals S-8 POS S-8 POS 1 d217084ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on July 5, 2016 Registration No. 333-207585 Registration No. 333-205860 Registration No. 333-202760 Registration No. 333-194803 Registration No. 333-189011 Registration No. 333-186249 Registration No. 333-180048 Registration No. 333-176173 Registration No. 333-171604 Registration No. 333-164843 Registration No |
|
| July 5, 2016 |
Alexza Pharmaceuticals S-8 POS S-8 POS As filed with the Securities and Exchange Commission on July 5, 2016 Registration No. |
|
| July 5, 2016 |
POS AM As filed with the Securities and Exchange Commission on July 5, 2016 Registration No. |
|
| July 5, 2016 |
POS AM As filed with the Securities and Exchange Commission on July 5, 2016 Registration No. |
|
| July 5, 2016 |
POS AM As filed with the Securities and Exchange Commission on July 5, 2016 Registration No. |
|
| July 1, 2016 |
Delisting of Securities of Alexza Pharmaceuticals, Inc. from The Nasdaq Stock Market EX-99.1 Exhibit 99.1 NEWS RELEASE - for immediate release Delisting of Securities of Alexza Pharmaceuticals, Inc. from The Nasdaq Stock Market Mountain View, California, July 1, 2016 / PRNewswire / ? Alexza Pharmaceuticals, Inc. (?Alexza? or the ?Company?) today announced that The Nasdaq Stock Market (?Nasdaq?) will delist the common stock of Alexza. Alexza?s stock was suspended on June 17, 2016 a |
|
| July 1, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2016 ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of incorporation) (Commissi |
|
| June 24, 2016 |
AMENDED AND RESTATED PROMISSORY NOTE $7,300,000 June 21, 2016 Mountain View, CA EX-10.1 2 d120752dex101.htm EX-10.1 Exhibit 10.1 THIS NOTE WAS ISSUED WITH ORIGINAL ISSUE DISCOUNT (“OID”) FOR U.S. FEDERAL INCOME TAX PURPOSES. THE ISSUE PRICE, AMOUNT OF OID, ISSUE DATE AND YIELD TO MATURITY WITH RESPECT TO THIS NOTE MAY BE OBTAINED BY WRITING TO BORROWER AT THE FOLLOWING ADDRESS: 2091 STIERLIN COURT, MOUNTAIN VIEW, CA 94043 ATTENTION: CHIEF EXECUTIVE OFFICER FAX NUMBER: (650) 9 |
|
| June 24, 2016 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2016 (June 21, 2016) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of inc |
|
| June 21, 2016 |
BYLAWS ALEXZA PHARMACEUTICALS, INC. (a Delaware Corporation) ALEXZA PHARMACEUTICALS, INC. ARTICLE I EX-3.2 2 d207994dex32.htm EX-3.2 Exhibit 3.2 BYLAWS OF ALEXZA PHARMACEUTICALS, INC. (a Delaware Corporation) ALEXZA PHARMACEUTICALS, INC. BYLAWS ARTICLE I OFFICES 1.1 Registered Office. The registered office of the Corporation in the State of Delaware is located at 850 New Burton Road, Suite 201, Kent County, Dover, DE 19904. 1.2 Offices. The Corporation may have offices at such places as the Boar |
|
| June 21, 2016 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2016 ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction (Commission (IRS Emplo |
|
| June 21, 2016 |
Alexza Pharmaceuticals Acquired by Ferrer EX-99.(a)(5)(H) Exhibit (a)(5)(H) NEWS RELEASE - for immediate release Alexza Pharmaceuticals Acquired by Ferrer Mountain View, California and Barcelona, Spain, June 21, 2016 / PRNewswire / ? Alexza Pharmaceuticals, Inc. (OTC: ALXA, ?Alexza?) and Grupo Ferrer Internacional, S.A. (?Ferrer?) today announced the expiration of the tender offer (the ?Offer?) by Ferrer Pharma Inc., a wholly-owned indire |
|
| June 21, 2016 |
Alexza Pharmaceuticals SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 3) ALEXZA PHARMACEUTICALS, INC. (Name of Subject Company) ALEXZA PHARMACEUTICALS, INC. (Name of Person Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securi |
|
| June 21, 2016 |
Alexza Pharmaceuticals SCHEDULE TO-T, AMENDMENT NO. 3 scto-ta3.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) ALEXZA PHARMACEUTICALS, INC. (Name of Subject Company (issuer)) Ferrer Pharma Inc. a wholly owned subsidiary of Ferrer Therapeutics Inc. a wholly owned subsidiary of Grupo Ferrer Internaci |
|
| June 16, 2016 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2016 (June 15, 2016) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of incorpo |
|
| June 16, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 Alexza Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 015384209 (CUSIP Number) Andrea |
|
| June 15, 2016 |
EX-1.01 2 d209836dex101.htm EX-1.01 Exhibit 1.01 Alexza Pharmaceuticals, Inc. Conflict Minerals Report For The Year Ended December 31, 2015 This report for the year ended December 31, 2015 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the Rule). For the purpose of the required Reasonable Country of Origin Inquiry (RCOI), Alexza continues to review its supply cha |
|
| June 15, 2016 |
SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT Alexza Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) DELAWARE 000-51820 77-0567768 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) 2091 Stierlin Court Mountain View, CA 94043 (Address of Principal Ex |
|
| June 15, 2016 |
Alexza Pharmaceuticals SCHEDULE TO-T, AMENDMENT NO. 2 scto-ta2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) ALEXZA PHARMACEUTICALS, INC. (Name of Subject Company (issuer)) Ferrer Pharma Inc. a wholly owned subsidiary of Ferrer Therapeutics Inc. a wholly owned subsidiary of Grupo Ferrer Internaci |
|
| June 13, 2016 |
Alexza Pharmaceuticals SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) ALEXZA PHARMACEUTICALS, INC. (Name of Subject Company) ALEXZA PHARMACEUTICALS, INC. (Name of Person Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securi |
|
| June 13, 2016 |
EX-99.(A)(5)(F) 2 d199551dex99a5f.htm EX-99.(A)(5)(F) Exhibit (a)(5)(F) Evan J. Smith (SBN242352) BRODSKY & SMITH, LLC 9595 Wilshire Boulevard, Suite 900 Beverly Hills, CA 90212 Telephone: (877) 534·2590 Facsimile: (310) 247-0160 [email protected] Counsel for Plaintiff [Additional Counsel Appears Below Signature Line] SUPERIOR COURT OF CALIFORNIA COUNTY OF SANTA CLARA PHILLIP KIM, Individua |
|
| June 13, 2016 |
CORRESP Brent D. Fassett +1 720 566 4025 [email protected] June 13, 2016 VIA EDGAR AND USPS United States Securities and Exchange Commission Office of Mergers and Acquisitions Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3628 Attn: Jennifer L?pez Re: Alexza Pharmaceuticals, Inc. Schedule 14D-9 filed on May 23, 2016, amended on June 3, 2016 SEC File No. 005-82505 Lad |
|
| June 3, 2016 |
EX-99.(A)(5)(F) 2 d199551dex99a5f.htm EX-99.(A)(5)(F) Exhibit (a)(5)(F) [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Evan J. Smith (SBN242352) BRODSKY & SMITH, LLC 9595 Wilshire Boulevard, Suite 900 Beverly Hills, CA 90212 Telepho |
|
| June 3, 2016 |
EX-99.(a)(5)(G) Exhibit (a)(5)(G) BRODSKY & SMITH, LLC Evan J. Smith (SBN 242352) [email protected] 9595 Wilshire Boulevard, Suite 900 Beverly Hills, CA 90212 Tel: (877) 534?2590 Fax: (310) 247-0160 Attorneys for Plaintiff [Additional Counsel Appears Below Signature Line] SUPERIOR COURT OF THE STATE OF CALIFORNIA COUNTY OF SANTA CLARA JOHN CANTY, on behalf of himself and all others similarl |
|
| June 3, 2016 |
Alexza Pharmaceuticals SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) ALEXZA PHARMACEUTICALS, INC. (Name of Subject Company) ALEXZA PHARMACEUTICALS, INC. (Name of Person Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securi |
|
| June 3, 2016 |
Alexza Pharmaceuticals SC TO-T, AMENDMENT NO. 1 scto-ta.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) ALEXZA PHARMACEUTICALS, INC. (Name of Subject Company (issuer)) Ferrer Pharma Inc. a wholly owned subsidiary of Ferrer Therapeutics Inc. a wholly owned subsidiary of Grupo Ferrer Internacio |
|
| June 3, 2016 |
CORRESP Brent D. Fassett +1 720 566 4025 [email protected] June 3, 2016 VIA EDGAR AND USPS United States Securities and Exchange Commission Office of Mergers and Acquisitions Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3628 Attn: Daniel F. Duchovny Re: Alexza Pharmaceuticals, Inc. Schedule 14D-9 filed on May 23, 2016 SEC File No. 005-82505 Ladies and Gentlemen: On |
|
| May 23, 2016 |
EX-99.(A)(5)(E) 2 d199551dex99a5e.htm EX-99.(A)(5)(E) Exhibit (a)(5)(E) Evan J. Smith (SBN242352) BRODSKY & SMITH, LLC 9595 Wilshire Boulevard, Suite 900 Beverly Hills, CA 90212 Telephone: (877) 534·2590 Facsimile: (310) 247-0160 [email protected] Attorneys for Plaintiff SUPERIOR COURT OF THE STATE OF CALIFORNIA COUNTY OF SANTA CLARA KEITH ANDERSON, on behalf of himself and all others simil |
|
| May 23, 2016 |
Alexza Pharmaceuticals SC 14D9 SC 14D9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 23, 2016 |
EX-99.(a)(1)(E) Exhibit (a)(1)(E) LETTER TO CLIENTS Offer by FERRER PHARMA INC., a wholly owned subsidiary of FERRER THERAPEUTICS INC., a wholly owned subsidiary of GRUPO FERRER INTERNACIONAL, S.A. to tender all outstanding shares of common stock of ALEXZA PHARMACEUTICALS, INC. for $0.90 Net Per Share in Cash plus One Non-Transferable Contractual Contingent Value Right for Each Share, which Repres |
|
| May 23, 2016 |
Alexza Pharmaceuticals SC TO-T SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 ALEXZA PHARMACEUTICALS, INC. (Name of Subject Company (issuer)) Ferrer Pharma Inc. a wholly owned subsidiary of Ferrer Therapeutics Inc. a wholly owned subsidiary of Grupo Ferrer Internacional, S.A. (Names of Fi |
|
| May 23, 2016 |
EX-99.(A)(1)(D) 5 d171578dex99a1d.htm EX-99.(A)(1)(D) Exhibit (a)(1)(D) LETTER TO BROKERS, DEALERS COMMERCIAL BANKS, TRUST COMPANIES AND OTHER NOMINEES Offer by FERRER PHARMA INC., a wholly owned subsidiary of FERRER THERAPEUTICS INC., a wholly owned subsidiary of GRUPO FERRER INTERNACIONAL, S.A. to tender all outstanding shares of common stock of ALEXZA PHARMACEUTICALS, INC. for $0.90 Net Per Sha |
|
| May 23, 2016 |
EX-99.(A)(1)(C) 4 d171578dex99a1c.htm EX-99.(A)(1)(C) Exhibit (a)(1)(C) Notice of Guaranteed Delivery for Offer to Purchase All Outstanding Shares of Common Stock of Alexza Pharmaceuticals, Inc. at for $0.90 Net Per Share in Cash plus One Non-Transferable Contractual Contingent Value Right for Each Share, which Represents the Right to Receive up to Four Categories of Contingent Cash Consideration |
|
| May 23, 2016 |
EX-99.(A)(1)(G) 8 d171578dex99a1g.htm EX-99.(A)(1)(G) Exhibit (a)(1)(G) FORM OF CONTINGENT VALUE RIGHTS AGREEMENT Table of Contents Article I DEFINITIONS; INTERPRETATION 1 Section 1.1 Definitions 1 Section 1.2 Treatment of Parent and its Affiliates; Transfer of Staccato Program 6 Section 1.3 Interpretation 7 Article II CONTINGENT VALUE RIGHTS 9 Section 2.1 Holders of CVRs; Appointment of Rights Ag |
|
| May 23, 2016 |
EX-99.(a)(1)(F) Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is made solely pursuant to the Offer to Purchase, dated May 23, 2016, and the related Letter of Transmittal, and any amendments or supplements to such Offer to Purchase or Letter of Transmittal. The Purchaser (as defined |
|
| May 23, 2016 |
EX-99.(A)(1)(A) 2 d171578dex99a1a.htm EX-99.(A)(1)(A) Table of Contents Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of ALEXZA PHARMACEUTICALS, INC. at $0.90 Net Per Share in Cash plus One Non-Transferable Contingent Value Right for each Share, which Represents the Right to Receive up to Four Categories of Contingent Cash Consideration Payments, if any, upon the Achie |
|
| May 23, 2016 |
EX-99.(A)(1)(B) 3 d171578dex99a1b.htm EX-99.(A)(1)(B) Exhibit (a)(1)(B) LETTER OF TRANSMITTAL To Tender Common Shares of Alexza Pharmaceuticals, Inc. for $0.90 Net Per Share in Cash plus One Non-Transferable Contractual Contingent Value Right for Each Share, which Represents the Right to Receive up to Four Categories of Contingent Cash Consideration Payments, if any, upon the Achievement of Certai |
|
| May 23, 2016 |
Grupo Ferrer Internacional, S.A. Diagonal 549, 5a planta E-08029 Barcelona, Spain EX-99.(d)(2) Exhibit (d)(2) Grupo Ferrer Internacional, S.A. Diagonal 549, 5a planta E-08029 Barcelona, Spain CONFIDENTIAL May 9, 2016 Alexza Pharmaceuticals Inc. 2091 Stierlin Court Mountain View, CA 94043 United States Attention: Ms. Tatjana Naranda Director Business Development & Global Alliance Management Dear Ms. Naranda, Reference is made to the Agreement and Plan of Merger (the ?Merger Agre |
|
| May 13, 2016 |
Alexza Pharmaceuticals 10-Q (Quarterly Report) 10-Q 1 alxa-10q20160331.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numb |
|
| May 13, 2016 |
AMENDMENT NO. 2 TO LICENSE AND SUPPLY AGREEMENT Execution Copy CONFIDENTIAL [*] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. |
|
| May 13, 2016 |
EX-10.4 5 alxa-ex104581.htm EX-10.4 Exhibit 10.4 Execution Version AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT BY AND BETWEEN ALEXZA PHARMACEUTICALS, INC. AND TEVA PHARMACEUTICALS USA, INC. Dated as of February 23, 2016 1 Exhibit 10.4 Execution Version REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made as of February 23, 2016, by and between Alexza P |
|
| May 13, 2016 |
AMENDED AND RESTATED PROMISSORY NOTE AND AGREEMENT TO LEND EX-10.2 3 alxa-ex102578.htm EX-10.2 Exhibit 10.2 Execution Version THIS AMENDED AND RESTATED PROMISSORY NOTE AND AGREEMENT TO LEND HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAW. NO SALE, TRANSFER, PLEDGE OR ASSIGNMENT OF THIS NOTE SHALL BE VALID OR EFFECTIVE UNLESS (A) SUCH TRANSFER IS MADE PURSUANT TO AN EFFECTIVE REGISTRA |
|
| May 13, 2016 |
ALEXZA PHARMACEUTICALS, INC. STOCK ISSUANCE AGREEMENT Exhibit 10.3 Execution Version ALEXZA PHARMACEUTICALS, INC. STOCK ISSUANCE AGREEMENT THIS STOCK ISSUANCE AGREEMENT (this “Agreement”) is made as of February 23, 2016, by and among Alexza Pharmaceuticals, Inc., a Delaware corporation (the “Company”), with its principal office at 2091 Stierlin Court, Mountain View, California 94043, and Teva Pharmaceuticals USA, Inc. (“Teva”). RECITALS WHEREAS, the |
|
| May 11, 2016 |
Alexza Pharmaceuticals SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ALEXZA PHARMACEUTICALS, INC. (Name of Subject Company) ALEXZA PHARMACEUTICALS, INC. (Name of Person Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 015384 209 (CUSIP Numb |
|
| May 11, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2016 ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of incorporation) (Comm |
|
| May 11, 2016 |
Alexza Reports 2016 First Quarter Financial Results EX-99.1 Exhibit 99.1 NEWS RELEASE - for immediate release Alexza Reports 2016 First Quarter Financial Results Mountain View, California, May 11, 2016 / PRNewswire / Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA, Alexza, or the Company) today reported financial results for the quarter ended March 31, 2016. The net loss for the first quarter was $3.4 million compared to $0.4 million during the sa |
|
| May 10, 2016 |
Alexza Pharmaceuticals SCHEDULE TO-C scto-c.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 ALEXZA PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) Ferrer Pharma Inc. a wholly owned subsidiary of Ferrer Therapeutics, Inc. a wholly owned subsidiary of Grupo Ferrer Internacional, S.A. (Names o |
|
| May 10, 2016 |
Alexza Pharmaceuticals SC14D9C SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ALEXZA PHARMACEUTICALS, INC. (Name of Subject Company) ALEXZA PHARMACEUTICALS, INC. (Name of Person Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 015384 209 (CU |
|
| May 10, 2016 |
AMENDED AND RESTATED PROMISSORY NOTE $6,300,000 May 9, 2016 Mountain View, CA EX-10.1 3 d185327dex101.htm EX-10.1 Exhibit 10.1 THIS NOTE WAS ISSUED WITH ORIGINAL ISSUE DISCOUNT (“OID”) FOR U.S. FEDERAL INCOME TAX PURPOSES. THE ISSUE PRICE, AMOUNT OF OID, ISSUE DATE AND YIELD TO MATURITY WITH RESPECT TO THIS NOTE MAY BE OBTAINED BY WRITING TO BORROWER AT THE FOLLOWING ADDRESS: 2091 STIERLIN COURT, MOUNTAIN VIEW, CA 94043 ATTENTION: CHIEF EXECUTIVE OFFICER FAX NUMBER: (650) 9 |
|
| May 10, 2016 |
Alexza Pharmaceuticals 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2016 (May 9, 2016) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of incorp |
|
| May 10, 2016 |
EX-2.1 2 d185327dex21.htm EX-2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER BY AND AMONG GRUPO FERRER INTERNACIONAL, S.A., FERRER PHARMA INC. AND ALEXZA PHARMACEUTICALS, INC. DATED AS OF MAY 9, 2016 TABLE OF CONTENTS PAGE Article I THE OFFER Section 1.1 The Offer 2 Section 1.2 Company Actions 5 Article II THE MERGER; CLOSING; EFFECTIVE TIME Section 2.1 The Merger 7 Section 2.2 Clos |
|
| May 10, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* ALEXZA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 015384209 (CUSIP Number) Jorge Ramentol Massana Grupo Ferrer Internacional, S.A. Avenida Diagonal 549, 5th Floor E-08029 Barcelona, Spain (34) 93 |
|
| April 29, 2016 |
Financial Statements and Exhibits, Other Events 8-K/A 1 d178428d8ka.htm FORM 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2016 ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other j |
|
| April 29, 2016 |
EX-10.1 2 d178428dex101.htm EX-10.1 Exhibit 10.1 Grupo Ferrer Internacional, S.A. Diagonal 549, 5a planta E-08029 Barcelona Tel. +34 936003700 - Fax +34 933308057 www.ferrer.com February 15th, 2016 Highly Confidential Alexza Pharmaceuticals Inc. 2091 Stierlin Court Mountain View, CA 94043 United States Attention: Ms. Tatjana Naranda Director Business Development & Global Alliance Management Ladies |
|
| April 29, 2016 |
Alexza Pharmaceuticals 10-K/A (Annual Report) alxa-10ka20151231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K/A x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51820 Alexza |
|
| April 29, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* ALEXZA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 015384209 (CUSIP Number) Jorge Ramentol Massana Grupo Ferrer Internacional, S.A. Avenida Diagonal 549, 5th Floor E-08029 Barcelona, Spain (34) 93 |
|
| April 29, 2016 |
Exhibit 99.1 Grupo Ferrer Internacional, S.A. Diagonal 549, 5a planta E-08029 Barcelona Tel. +34 936003700 - Fax +34 933308057 www.ferrer.com February 15th, 2016 Highly Confidential Alexza Pharmaceuticals Inc. 2091 Stierlin Court Mountain View, CA 94043 United States Attention: Ms. Tatjana Naranda Director Business Development & Global Alliance Management Ladies and Gentleman: Over the course of t |
|
| April 15, 2016 |
EXHIBIT 10.1 THIS NOTE WAS ISSUED WITH ORIGINAL ISSUE DISCOUNT (?OID?) FOR U.S. FEDERAL INCOME TAX PURPOSES. THE ISSUE PRICE, AMOUNT OF OID, ISSUE DATE AND YIELD TO MATURITY WITH RESPECT TO THIS NOTE MAY BE OBTAINED BY WRITING TO BORROWER AT THE FOLLOWING ADDRESS: 2091 STIERLIN COURT, MOUNTAIN VIEW, CA 94043 ATTENTION: CHIEF EXECUTIVE OFFICER FAX NUMBER: (650) 944-7999 PROMISSORY NOTE $5,000,000 S |
|
| April 15, 2016 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits Form 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2016 ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of incorpora |
|
| March 28, 2016 |
Alexza Pharmaceuticals 10-K (Annual Report) alxa-10k20151231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51820 Alexza Ph |
|
| March 28, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2016 ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of incorporation |
|
| March 28, 2016 |
EX-99.1 Exhibit 99.1 NEWS RELEASE - for immediate release Alexza Reports Fourth Quarter and Year End 2015 Financial Results Management to Review Results and Provide General Update in Conference Call Scheduled Today for 5:00 p.m. Eastern Time Mountain View, California?March 28, 2016 - Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA, ?Alexza?, or the ?Company?) today reported financial results for the qu |
|
| March 28, 2016 |
Exhibit 21.1 Subsidiaries of Registrant Name of Subsidiary Jurisdiction of Incorporation Names Under Which Subsidiary Does Business Alexza UK Limited United Kingdom Alexza UK Limited Symphony Allegro, Inc. Delaware Symphony Allegro, Inc. Atlas U.S. Royalty, LLC Delaware Atlas U.S. Royalty, LLC |
|
| March 28, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ALEXZA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) CUSIP 015384 209 February 23, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| March 28, 2016 |
Exhibit A JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned, each referred to herein as a “Joint Filer”, agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereof) with respect to the beneficial ownership of certain shares of Common Stock of Alexza Pharmaceuticals, Inc. |
|
| March 24, 2016 |
PROMISSORY NOTE $5,000,000 September 28, 2015 Amended March 21, 2016 Mountain View, CA EX-10.1 Exhibit 10.1 THIS NOTE WAS ISSUED WITH ORIGINAL ISSUE DISCOUNT (?OID?) FOR U.S. FEDERAL INCOME TAX PURPOSES. THE ISSUE PRICE, AMOUNT OF OID, ISSUE DATE AND YIELD TO MATURITY WITH RESPECT TO THIS NOTE MAY BE OBTAINED BY WRITING TO BORROWER AT THE FOLLOWING ADDRESS: 2091 STIERLIN COURT, MOUNTAIN VIEW, CA 94043 ATTENTION: CHIEF EXECUTIVE OFFICER FAX NUMBER: (650) 944-7999 PROMISSORY NOTE $5,0 |
|
| March 24, 2016 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits Form 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2016 (March 21, 2016) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdic |
|
| March 9, 2016 |
Alexza Pharmaceuticals Receives Positive Nasdaq Listing Determination EX-99.1 Exhibit 99.1 NEWS RELEASE - for immediate release Alexza Pharmaceuticals Receives Positive Nasdaq Listing Determination Mountain View, California, March 9, 2016 - Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA, ?Alexza,? or the ?Company?) announced today that on March 7, 2016 the Nasdaq Listing Qualifications Panel (the ?Panel?) issued a determination granting the Company?s request for the con |
|
| March 9, 2016 |
Alexza Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2016 (March 7, 2016) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction o |
|
| February 29, 2016 |
Alexza Pharmaceuticals Confirms Grupo Ferrer Non-binding Letter of Intent EX-99.1 Exhibit 99.1 NEWS RELEASE - for immediate release Alexza Pharmaceuticals Confirms Grupo Ferrer Non-binding Letter of Intent Mountain View, California, February 26, 2016 - Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA, Alexza, or the Company) announced today that on February 15, 2016 it had entered into a non-binding letter of intent (the Letter of Intent) with Grupo Ferrer Internacional, |
|
| February 29, 2016 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2016 (February 26, 2016) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisd |
|
| February 26, 2016 |
Grupo Ferrer Internacional, S.A. Exhibit 99.1 Grupo Ferrer Internacional, S.A. Diagonal 549, 5a planta E-08029 Barcelona Tel. +34 936003700 - Fax +34 933308057 www.ferrer.com February 15th, 2016 Highly Confidential Alexza Pharmaceuticals Inc. 2091 Stierlin Court Mountain View, CA 94043 United States Attention: Ms. Tatjana Naranda Director Business Development & Global Alliance Management Ladies and Gentleman: Over the course of t |
|
| February 26, 2016 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) Exhibit 99.6 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13D in respect of the common stock, $0.0001 par value of Alexza Pharmaceuticals, Inc. is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D may be filed on behalf of each of the undersigned without |
|
| February 26, 2016 |
ALXA / Alexza Pharmaceuticals, Inc. / Grupo Ferrer Internacional, S.A. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934* ALEXZA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 015384209 (CUSIP Number) Jorge Ramentol Massana Grupo Ferrer Internacional, S.A. Avenida Diagonal 549, 5th Floor E-08029 Barcelona, Spain (34) 936003-700 (Name, Ad |
|
| February 24, 2016 |
Alexza Pharmaceuticals Reacquires U.S. Commercial Rights for ADASUVE® (loxapine) inhalation powder EX-99.1 Exhibit 99.1 NEWS RELEASE - for immediate release Alexza Pharmaceuticals Reacquires U.S. Commercial Rights for ADASUVE? (loxapine) inhalation powder Mountain View, California, February 24, 2016 - Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has reacquired U.S. commercial rights for ADASUVE? (loxapine) inhalation powder from Teva Pharmaceuticals USA, Inc., a subsidiar |
|
| February 24, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2016 (February 23, 2016) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisd |
|
| February 12, 2016 |
ALXA / Alexza Pharmaceuticals, Inc. / Grupo Ferrer Internacional, S.A. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Amendment No. 1) UNDER THE SECURITIES EXCHANGE ACT OF 1934 ALEXZA PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE (Title of Class of Securities) 015384 209 (CUSIP Number) DECEMBER 31, 2015 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designat |
|
| January 22, 2016 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2016 (January 20, 2016) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of i |
|
| December 22, 2015 |
EX-99.1 Exhibit 99.1 NEWS RELEASE ? for immediate release Alexza Pharmaceuticals Announces Receipt of NASDAQ Staff Determination; Alexza to Request Hearing with NASDAQ Listing Qualifications Panel Mountain View, California ? December 22, 2015 ? Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that on December 17, 2015, the Company received a letter from the Nasdaq Staff indicating that |
|
| December 22, 2015 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2015 (December 17, 2015) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisd |
|
| December 21, 2015 |
Alexza Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2015 ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of incorporat |
|
| December 21, 2015 |
EX-99.1 Exhibit 99.1 NEWS RELEASE - for immediate release Alexza Pharmaceuticals Announces Interim Results from its Phase 2a Study of AZ-002 (Staccato? alprazolam) in Epilepsy Patients Interim Analysis Shows That AZ-002 Produces Dose-Related Decreases in Mean Standardized Photosensitivity Range Mountain View, California - December 21, 2015 - Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announ |
|
| November 17, 2015 |
ALEXZA PHARMACEUTICALS, INC. Common Stock Prospectus Supplement No. 6 (to Prospectus dated April 23, 2010) Filed Pursuant to Rule 424(b)(3) Registration No. 333-162582 ALEXZA PHARMACEUTICALS, INC. Common Stock This Prospectus Supplement No. 6 supplements and amends the prospectus dated April 23, 2010 (the Prospectus), as supplemented and amended by that certain Prospectus Supplement No. 1 dated October 26, 2010, that certain Prospectus |
|
| November 5, 2015 |
EX-99.1 Exhibit 99.1 NEWS RELEASE ? for immediate release Alexza Reports 2015 Third Quarter Financial Results Management to Review Results and Provide Business Update in Conference Call Scheduled Today at 5:00 p.m. Eastern Time Mountain View, California, November 5, 2015 ? Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the quarter ended September 30, 2015. The net |
|
| November 5, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2015 ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of incorporation) ( |
|
| October 30, 2015 |
Exhibit 99.1 Exhibit 99.1 NEWS RELEASE - for immediate release Alexza Pharmaceuticals Announces Intent to Reacquire U.S. Rights for ADASUVE? (loxapine) inhalation powder Mountain View, California, October 30, 2015 - Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it plans to reacquire the U.S. rights for ADASUVE? (loxapine) inhalation powder from Teva Pharmaceuticals USA, Inc., a |
|
| October 30, 2015 |
Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2015 ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of incorporation) (Comm |
|
| October 30, 2015 |
Alexza Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2015 (October 26, 2015) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdic |
|
| October 23, 2015 |
EX-99.1 EXHIBIT 99.1 ALEXZA PHARMACEUTICALS, INC. 2015 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: APRIL 27, 2015 APPROVED BY THE STOCKHOLDERS: JUNE 23, 2015 EFFECTIVE DATE: JUNE 23, 2015 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of Comm |
|
| October 23, 2015 |
S-8 As filed with the Securities and Exchange Commission on October 23, 2015 Registration No. |
|
| October 14, 2015 |
EX-99.1 Exhibit 99.1 NEWS RELEASE - for immediate release Ferrer and Alexza Pharmaceuticals Provide Update on ADASUVE? European and Latin American Commercial Activities Barcelona, Spain - October 14, 2015 - Grupo Ferrer Internacional, SA (Ferrer) and Alexza Pharmaceuticals, Inc. (Alexza, Nasdaq: ALXA) today provided an update on the commercial activities related to ADASUVE? inhalation powder, pre- |
|
| October 14, 2015 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2015 ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction (Commission (IRS Em |
|
| October 13, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2015 (October 6, 2015) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of in |
|
| October 2, 2015 |
Alexza Pharmaceuticals Announces Management Promotions EX-99.1 Exhibit 99.1 NEWS RELEASE - for immediate release Alexza Pharmaceuticals Announces Management Promotions Mountain View, California - October 2, 2015 - Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced two management promotions. Catherine McAuliffe has been promoted to the newly created position of Vice President, Operations. In this new role, Ms. McAuliffe will be responsible for |
|
| October 2, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2015 (September 29, 2015) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of |
|
| September 28, 2015 |
PROMISSORY NOTE $5,000,000 September 28, 2015 Mountain View, CA EX-10.1 Exhibit 10.1 THIS NOTE WAS ISSUED WITH ORIGINAL ISSUE DISCOUNT (?OID?) FOR U.S. FEDERAL INCOME TAX PURPOSES. THE ISSUE PRICE, AMOUNT OF OID, ISSUE DATE AND YIELD TO MATURITY WITH RESPECT TO THIS NOTE MAY BE OBTAINED BY WRITING TO BORROWER AT THE FOLLOWING ADDRESS: 2091 STIERLIN COURT, MOUNTAIN VIEW, CA 94043 ATTENTION: CHIEF EXECUTIVE OFFICER FAX NUMBER: (650) 944-7999 PROMISSORY NOTE $5,0 |
|
| September 28, 2015 |
Alexza Pharmaceuticals 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2015 ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction (Commission (IRS |
|
| September 28, 2015 |
Alexza Retains Guggenheim Securities, LLC to Explore Strategic Options EX-99.1 Exhibit 99.1 NEWS RELEASE - for immediate release Alexza Retains Guggenheim Securities, LLC to Explore Strategic Options Mountain View, California - September 28, 2015 - Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has retained Guggenheim Securities, LLC to assist in exploring strategic options to enhance stockholder value, including a possible sale or disposition of |
|
| September 28, 2015 |
ALEXZA PHARMACEUTICALS, INC. STOCK ISSUANCE AGREEMENT EX-10.2 3 d33345dex102.htm EX-10.2 Exhibit 10.2 ALEXZA PHARMACEUTICALS, INC. STOCK ISSUANCE AGREEMENT THIS STOCK ISSUANCE AGREEMENT (this “Agreement”) is made as of September 28, 2015, by and among ALEXZA PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), with its principal office at 2091 Stierlin Court, Mountain View, California 94043, and GRUPO FERRER INTERNACIONAL, S.A. (“Ferrer”). |
|
| August 6, 2015 |
EX-99.1 2 d75150dex991.htm EX-99.1 Exhibit 99.1 NEWS RELEASE - for immediate release Alexza Reports 2015 Second Quarter Financial Results Management to Review Results and Provide Business Update in Conference Call Scheduled Today at 5:00 p.m. Eastern Time Mountain View, California, August 6, 2015 - Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the quarter ended J |
|
| August 6, 2015 |
Alexza Pharmaceuticals 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2015 ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of incorporation) (Co |
|
| August 3, 2015 |
ALXA / Alexza Pharmaceuticals, Inc. / LANSDOWNE PARTNERS AUSTRIA GMBH Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| July 24, 2015 |
EXHIBIT 99.4 ALEXZA PHARMACEUTICALS, INC. 2015 NON-EMPLOYEE DIRECTORS STOCK AWARD PLAN ADOPTED BY THE BOARD OF DIRECTORS: APRIL 27, 2015 APPROVED BY THE STOCKHOLDERS: JUNE 23, 2015 EFFECTIVE DATE: JUNE 23, 2015 1. GENERAL. (a) Successor to and Continuation of Prior Plan. The Plan is intended as the successor to and continuation of the Alexza Pharmaceuticals, Inc. 2005 Non-Employee Directors Stoc |
|
| July 24, 2015 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2015 (July 22, 2015) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of inc |
|
| July 24, 2015 |
EX-99.5 8 d25013dex995.htm EX-99.5 EXHIBIT 99.5 ALEXZA PHARMACEUTICALS, INC. STOCK OPTION GRANT NOTICE (2015 NON-EMPLOYEE DIRECTORS’ STOCK AWARD PLAN) Alexza Pharmaceuticals, Inc. (the “Company”), pursuant to its 2015 Non-Employee Directors’ Stock Award Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This op |
|
| July 24, 2015 |
ALEXZA PHARMACEUTICALS, INC. STOCK OPTION GRANT NOTICE (2015 EQUITY INCENTIVE PLAN) EX-99.2 EXHIBIT 99.2 ALEXZA PHARMACEUTICALS, INC. STOCK OPTION GRANT NOTICE (2015 EQUITY INCENTIVE PLAN) Alexza Pharmaceuticals, Inc. (the ?Company?), pursuant to its 2015 Equity Incentive Plan (the ?Plan?), hereby grants to Optionholder an option to purchase the number of shares of the Company?s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth i |
|
| July 24, 2015 |
ALEXZA PHARMACEUTICALS, INC. RESTRICTED STOCK UNIT GRANT NOTICE (2015 EQUITY INCENTIVE PLAN) EXHIBIT 99.3 ALEXZA PHARMACEUTICALS, INC. RESTRICTED STOCK UNIT GRANT NOTICE (2015 EQUITY INCENTIVE PLAN) Alexza Pharmaceuticals, Inc. (the Company), pursuant to Section 6(b) of the Companys 2015 Equity Incentive Plan (the Plan), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Companys Common Stock (Restricted Stock Units) set forth below (the Aw |
|
| July 24, 2015 |
Alexza Pharmaceuticals FORM S-8 Form S-8 As filed with the Securities and Exchange Commission on July 24, 2015 Registration No. |
|
| July 24, 2015 |
EX-99.1 EXHIBIT 99.1 ALEXZA PHARMACEUTICALS, INC. 2015 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: APRIL 27, 2015 APPROVED BY THE STOCKHOLDERS: JUNE 23, 2015 EFFECTIVE DATE: JUNE 23, 2015 1. GENERAL. (a) Successor to and Continuation of the 2005 Equity Incentive Plan. The Plan is intended as the successor to and continuation of the Alexza Pharmaceuticals, Inc. 2005 Equity Incentive Pl |
|
| June 25, 2015 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2015 (June 23, 2015) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of incorpo |
|
| June 23, 2015 |
Alexza Pharmaceuticals 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2015 (June 19, 2015) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of inc |
|
| June 18, 2015 |
Alexza Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2015 ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of incorporation) |
|
| June 18, 2015 |
Exhibit 99.1 NEWS RELEASE - for immediate release Alexza Amends ADASUVE® Commercial Partnership Agreements Ferrer to Assume Additional Financial, Clinical, Regulatory and Commercial Responsibilities Teva Note Maturity Extended with no Interest Accrual for Specified Period of Time Mountain View, California - June 18, 2015 - Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced that it has upd |
|
| June 11, 2015 |
EX-16.1 Exhibit 16.1 June 11, 2015 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read Item 4.01 of Form 8-K dated June 11, 2015, of Alexza Pharmaceuticals, Inc. and are in agreement with the statements contained in the first sentence of the first paragraph, the second, third and fourth paragraphs on page 2 therein. We have no basis to agre |
|
| June 11, 2015 |
Alexza Pharmaceuticals 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2015 (June 5, 2015) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of inco |
|
| June 8, 2015 |
Alexza Pharmaceuticals DEFINITIVE PROXY STATEMENT (AMENDMENT 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| May 27, 2015 |
Alexza Pharmaceuticals, Inc. Conflict Minerals Report For The Year Ended December 31, 2014 EX-1.01 Exhibit 1.01 Alexza Pharmaceuticals, Inc. Conflict Minerals Report For The Year Ended December 31, 2014 This report for the year ended December 31, 2014 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the Rule). For the purpose of the required Reasonable Country of Origin Inquiry (RCOI), Alexza continues to review its supply chain. The Rule was adopted by |
|
| May 27, 2015 |
SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT Alexza Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) DELAWARE 000-51820 77-0567768 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) 2091 Stierlin Court Mountain View, CA 94043 (Address of Principal Ex |
|
| May 22, 2015 |
CONFIDENTIAL RELEASE AGREEMENT EX-10.1 Exhibit 10.1 CONFIDENTIAL RELEASE AGREEMENT Alexza Pharmaceuticals, Inc. (?Company?) has agreed that, in return for my signing this Release Agreement (the ?Agreement?) and allowing it to become effective as specified below, the Company will provide me with the consideration (the ?Severance Benefits?) described in its May 18, 2015 letter to me (attached hereto as Exhibit A, subject to the c |
|
| May 22, 2015 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2015 (May 20, 2015) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of |
|
| May 6, 2015 |
EX-99.1 2 d921709dex991.htm EX-99.1 Exhibit 99.1 NEWS RELEASE - for immediate release Alexza Reports 2015 First Quarter Financial Results Management to Review Results and Provide a General Update in a Conference Call Scheduled Today for 5:00 p.m. Eastern Time Mountain View, California - May 6, 2015 - Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the quarter ended |
|
| May 6, 2015 |
Alexza Pharmaceuticals 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2015 ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of incorporation) (Commi |
|
| April 30, 2015 |
Alexza Pharmaceuticals DEFINITIVE PROXY STATEMENT Definitive Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 30, 2015 |
Alexza Pharmaceuticals DEFINITIVE ADDITIONAL MATERIALS Definitive Additional Materials UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 29, 2015 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2015 (April 28, 2015) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction |
|
| April 29, 2015 |
Alexza Pharmaceuticals Announces Management Promotions EX-99.1 Exhibit 99.1 NEWS RELEASE?for immediate release Alexza Pharmaceuticals Announces Management Promotions Mountain View, California ? April 29, 2015 - Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced two management promotions. Dr. Edwin S. Kamemoto has been promoted to the newly created position of Executive Vice President, R&D and Quality. In this new role, Dr. Kamemoto will be re |
|
| March 13, 2015 |
Alexza Pharmaceuticals FORM S-8 Form S-8 As filed with the Securities and Exchange Commission on March 13, 2015 Registration No. |
|
| March 9, 2015 |
Alexza Pharmaceuticals FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2015 ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of incorporation) |
|
| March 9, 2015 |
EX-99.1 Exhibit 99.1 NEWS RELEASE - for immediate release Alexza Reports Fourth Quarter and Year End 2014 Financial Results Management to Review Results and Provide General Update in Conference Call Scheduled Today for 5:00 p.m. Eastern Time Mountain View, California - March 9, 2015 - Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the quarter and year ended Decemb |
|
| February 17, 2015 |
ALEXZA PHARMACEUTICALS, INC. 2015 CASH BONUS PLAN EX-10.1 2 d876681dex101.htm EX-10.1 Exhibit 10.1 ALEXZA PHARMACEUTICALS, INC. 2015 CASH BONUS PLAN 1. GENERAL. (a) Eligible Bonus Award Recipients. The persons eligible to receive Bonus Awards are Alexza employees. (b) Form of Bonus Awards. All Bonus Awards under the Bonus Plan will be paid in cash. (c) Purpose. The Company, by means of the Bonus Plan, seeks to secure and retain the services of th |
|
| February 17, 2015 |
ALXA / Alexza Pharmaceuticals, Inc. / LANSDOWNE PARTNERS AUSTRIA GMBH Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No. |
|
| February 17, 2015 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2015 (February 15, 2015) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdictio |
|
| January 23, 2015 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2015 (January 19, 2015) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdic |
|
| January 22, 2015 |
EX-99.1 Exhibit 99.1 NEWS RELEASE - for immediate release Alexza Pharmaceuticals Initiates Phase 2a Study of AZ-002 (Staccato® alprazolam) in Epilepsy Patients Mountain View, California - January 22, 2015 - Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has initiated a Phase 2a study of AZ-002 (Staccato® alprazolam), which is being developed for the management of epilepsy in p |
|
| January 22, 2015 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2015 ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of incorporati |
|
| December 23, 2014 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2014 (December 18, 2014) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdictio |
|
| December 16, 2014 |
Alexza Amends Autoliv Agreement for Heat Packages Used in ADASUVE® EX-99.1 Exhibit 99.1 NEWS RELEASE - for immediate release Alexza Amends Autoliv Agreement for Heat Packages Used in ADASUVE® Mountain View, California - December 16, 2014 - Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced that it amended its commercial Manufacturing and Supply Agreement (“Supply Agreement”) with Autoliv ASP Inc., the North American subsidiary of Sweden-based Autoliv Inc |
|
| December 16, 2014 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2014 (December 11, 2014) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisd |
|
| November 5, 2014 |
EX-99.1 Exhibit 99.1 NEWS RELEASE - for immediate release Alexza Reports 2014 Third Quarter Financial Results Management to Review Results and Provide Business Update in Conference Call Scheduled Today at 5:00 p.m. Eastern Time Mountain View, California, November 5, 2014 - Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the quarter ended September 30, 2014. The net |
|
| November 5, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2014 ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of incorporation) ( |
|
| November 3, 2014 |
ALXA / Alexza Pharmaceuticals, Inc. / Grupo Ferrer Internacional, S.A. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 ALEXZA PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE (Title of Class of Securities) 015384 209 (CUSIP Number) OCTOBER 27, 2014 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant t |
|
| October 31, 2014 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2014 (October 27, 2014) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdic |
|
| October 27, 2014 |
EX-99.1 Exhibit 99.1 NEWS RELEASE - for immediate release Alexza and Ferrer Expand ADASUVE® Partnership Ferrer Purchases $8 Million of Alexza Common Stock through New Investment and Elimination of Potential Milestone Payments Mountain View, California and Barcelona, Spain - October 27, 2014 - Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) and Grupo Ferrer Internacional, S.A. (Ferrer) announced today |
|
| October 27, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2014 (October 24, 2014) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdic |
|
| October 9, 2014 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2014 ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of incorporation) (C |
|
| October 9, 2014 |
EX-99.1 2 d803101dex991.htm EX-99.1 Exhibit 99.1 NEWS RELEASE - for immediate release Alexza Pharmaceuticals Provides Update on ADASUVE® U.S. Commercial Progress ADASUVE Initial Product Inventory Stocking Completed Mountain View, California - October 9, 2014 - Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today provided an update on the U.S. commercial progress with ADASUVE® (loxapine) inhalation po |
|
| September 18, 2014 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2014 ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction (Commission (IRS |
|
| September 18, 2014 |
Alexza Pharmaceuticals and Ferrer Provide Update on ADASUVE® European Commercial Activities EX-99.1 Exhibit 99.1 NEWS RELEASE - for immediate release Alexza Pharmaceuticals and Ferrer Provide Update on ADASUVE® European Commercial Activities Mountain View, California - September 18, 2014 - Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today provided an update on the commercial activities related to ADASUVE® inhalation powder, pre-dispensed (Staccato® loxapine) in the European Union (EU). G |
|
| September 10, 2014 |
ALXA / Alexza Pharmaceuticals, Inc. / FEDERATED INVESTORS INC /PA/ Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ALEXZA PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 015384100 (CUSIP Number) August 29, 2014 (Date of Event Which Requires Filing of |
|
| August 7, 2014 |
EX-99.1 Exhibit 99.1 NEWS RELEASE - for immediate release Alexza Reports 2014 Second Quarter Financial Results Management to Review Results and Provide Business Update in Conference Call Scheduled Today at 5:00 p.m. Eastern Time Mountain View, California, August 7, 2014 - Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the quarter ended June 30, 2014. The net loss |
|
| August 7, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2014 ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of incorporation) (Co |
|
| July 31, 2014 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2014 ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of incorporation) |
|
| July 8, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2014 (July 7, 2014) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of |
|
| June 30, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2014 (June 27, 2014) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction o |
|
| June 30, 2014 |
EX-99.1 Exhibit 99.1 NEWS RELEASE – for immediate release Alexza Announces the Promotion of Edwin S. Kamemoto, Ph.D. to Senior Vice President, Regulatory Affairs Mountain View, California—June 30, 2014 - Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced the promotion of Edwin S. Kamemoto, Ph.D., to the newly created position of Senior Vice President, Regulatory Affairs. Dr. Kamemoto will |
|
| June 16, 2014 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2014 (June 13, 2014) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction (Commi |
|
| June 11, 2014 |
Submission of Matters to a Vote of Security Holders - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2014 (June 10, 2014) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of inc |
|
| June 2, 2014 |
Form SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT Alexza Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) DELAWARE 000-51820 77-0567768 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) 2091 Stierlin Court Mountain View, CA 94043 (Address of Princip |
|
| June 2, 2014 |
Alexza Pharmaceuticals, Inc. Conflict Minerals Report For The Year Ended December 31, 2013 Exhibit 1.02 Alexza Pharmaceuticals, Inc. Conflict Minerals Report For The Year Ended December 31, 2013 This report for the year ended December 31, 2013 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the Rule). For the purpose of the required Reasonable Country of Origin Inquiry (RCOI), Alexza continues to review its supply chain. The Rule was adopted by the Secu |
|
| May 5, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2014 (May 5, 2014) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of incorpo |
|
| May 5, 2014 |
EX-99.1 Exhibit 99.1 NEWS RELEASE - for immediate release Alexza Reports 2014 First Quarter Financial Results Management to Review Results and Provide Business Update in Conference Call Scheduled Today for 5:00 p.m. Eastern Time Mountain View, California, May 5, 2014 - Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the quarter ended March 31, 2014. The net loss fo |
|
| April 30, 2014 |
Definitive Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 30, 2014 |
- DEFINITIVE ADDITIONAL MATERIALS Definitive Additional Materials UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 17, 2014 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2014 (April 16, 2014) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of i |
|
| April 17, 2014 |
Winston R. Brown, Jr. Joins Alexza Pharmaceuticals as Vice President, Quality EX-99.1 Exhibit 99.1 NEWS RELEASE - for immediate release Winston R. Brown, Jr. Joins Alexza Pharmaceuticals as Vice President, Quality Mountain View, California - April 17, 2014 - Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that Winston R. Brown, Jr. has joined the Company as Vice President, Quality. Mr. Brown brings more than two decades of experience in global quality, regulator |
|
| March 25, 2014 |
S-8 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ALEXZA PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 77-0567768 (State of Incorporation) (I.R.S. Employer Identification No.) Alexza Pharmaceuticals, Inc. 2091 Stierlin Court Mountain View, Califor |
|
| March 25, 2014 |
Alexza Pharmaceuticals 10-K (Annual Report) 10-K 1 d663753d10k.htm 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Nu |
|
| March 19, 2014 |
EX-99.1 Exhibit 99.1 NEWS RELEASE - for immediate release Alexza Pharmaceuticals Announces Private Placement of $45 Million of Non-Recourse Notes Notes Secured by Royalties and Milestones on U.S. Sales of ADASUVE® Mountain View, California - March 19, 2014 - Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) (Alexza) announced today that it has closed a private placement to institutional investors of $45 |
|
| March 19, 2014 |
8-K 1 d695900d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2014 (March 18, 2014) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State |
|
| March 6, 2014 |
EX-99.1 Exhibit 99.1 NEWS RELEASE - for immediate release Alexza Reports Fourth Quarter and Year End 2013 Financial Results Management to Review Results and Provide Business Update in Conference Call Scheduled Today for 5:00 p.m. Eastern Time Mountain View, California - March 6, 2014 - Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the quarter and year ended Decem |
|
| March 6, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2014 ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction (Commission (IRS Employer |
|
| March 3, 2014 |
EX-99.1 2 d687036dex991.htm EX-99.1 Exhibit 99.1 NEWS RELEASE - for immediate release Alexza Announces the U.S. Commercial Launch of ADASUVE® by Teva Pharmaceuticals ADASUVE is the first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults Mountain View, CA, March 3, 2014 - Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) to |
|
| March 3, 2014 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2014 (March 3, 2014) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of incorpo |
|
| February 26, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2014 (February 24, 2014) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of |
|
| February 26, 2014 |
EX-99.1 Exhibit 99.1 NEWS RELEASE - for immediate release Robert A. Lippe Joins Alexza Pharmaceuticals as Executive Vice President, Operations and Chief Operations Officer Mountain View, California - February 25, 2014 - Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that Robert A. Lippe has joined the Company as Executive Vice President, Operations and Chief Operations Officer. In thi |
|
| February 14, 2014 |
ALXA / Alexza Pharmaceuticals, Inc. / LANSDOWNE PARTNERS AUSTRIA GMBH Passive Investment SC 13G/A 1 d145036513g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No. 3 ALEXZA PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of Securities) 015384209 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| February 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* ALEXZA PHARMACEUTICALS INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 015384209 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| February 12, 2014 |
ALXA / Alexza Pharmaceuticals, Inc. / FEDERATED INVESTORS INC /PA/ Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ALEXZA PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 015384100 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing |
|
| January 24, 2014 |
ALEXZA PHARMACEUTICALS, INC. 2014 CASH BONUS PLAN EX-10.1 Exhibit 10.1 ALEXZA PHARMACEUTICALS, INC. 2014 CASH BONUS PLAN 1. GENERAL. (a) Eligible Bonus Award Recipients. The persons eligible to receive Bonus Awards are all Alexza employees. (b) Form of Bonus Awards. All Bonus Awards under the Bonus Plan will be paid in cash. (c) Purpose. The Company, by means of the Bonus Plan, seeks to secure and retain the services of the group of persons eligi |
|
| January 24, 2014 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2014 (January 21, 2014) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction |
|
| January 21, 2014 |
EX-99.1 Exhibit 99.1 NEWS RELEASE - for immediate release Alexza Pharmaceuticals Announces Ferrer’s Launch of ADASUVE® (Staccato® Loxapine) in Spain Triggering a $1 Million Milestone Payment Mountain View, California - January 21, 2014 - Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced that ADASUVE® inhalation powder, pre-dispensed (Staccato® loxapine) is now available in Spain through |
|
| January 21, 2014 |
Financial Statements and Exhibits, Other Events - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2014 (January 21, 2014) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction |
|
| January 8, 2014 |
ALXA / Alexza Pharmaceuticals, Inc. / CREDIT SUISSE AG/ - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* Alexza Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 015384209 (CUSIP Number) Calendar Year 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| January 8, 2014 |
In accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998), this Statement is being filed by Credit Suisse AG (the "Bank"), a Swiss bank, on behalf of its subsidiaries to the extent that they constitute the Investment Banking Division (the "Investment Banking Division") and the Alternative Investments business (the "AI Business") and U.S. private client services |
|
| January 8, 2014 |
ALXA / Alexza Pharmaceuticals, Inc. / CREDIT SUISSE - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* Alexza Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 015384209 (CUSIP Number) Calendar Year 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| January 8, 2014 |
In accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998), this Statement is being filed by Credit Suisse AG (the "Bank"), a Swiss bank, on behalf of its subsidiaries to the extent that they constitute the Private Banking and Wealth Management Division other than the Alternative Investments business (the "AI Business") and U.S. private client services business ( |
|
| December 20, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2013 (December 19, 2013) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisd |
|
| December 12, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2013 (December 11, 2013) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of |
|
| November 22, 2013 |
ALEXZA PHARMACEUTICALS, INC. Common Stock Prospectus Supplement No. 5 (to Prospectus dated April 23, 2010) Filed Pursuant to Rule 424(b)(3) Registration No. 333-162582 ALEXZA PHARMACEUTICALS, INC. Common Stock This Prospectus Supplement No. 5 supplements and amends the prospectus dated April 23, 2010 (the “Prospectus”), as supplemented and amended by that certain Prospectus Supplement No. 1 dated October 26, 2010, that certain Prospectus |
|
| November 6, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2013 ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of incorporati |
|
| November 6, 2013 |
EX-99.1 Exhibit 99.1 NEWS RELEASE – for immediate release Alexza Reports 2013 Third Quarter Financial Results Management to Review Results and Provide Business Update in Conference Call Scheduled Today for 5:00 p.m. Eastern Time Mountain View, California—November 6, 2013 - Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the quarter ended September 30, 2013. The net |
|
| November 1, 2013 |
Termination of a Material Definitive Agreement Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2013 (October 29, 2013) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdic |
|
| September 30, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2013 (September 27, 2013) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other juri |
|
| August 16, 2013 |
FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2013 (August 14, 2013) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdicti |
|
| August 8, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2013 ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction (Commission (IRS |
|
| August 8, 2013 |
EX-99.1 Exhibit 99.1 NEWS RELEASE - for immediate release Alexza Reports Preliminary 2013 Second Quarter Financial Results Management to Review Results and Provide Business Update in Conference Call Scheduled Today for 5:00 p.m. Eastern Time Mountain View, California - August 8, 2013 - Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported preliminary financial results for the quarter ended Ju |
|
| July 30, 2013 |
Financial Statements and Exhibits, Other Events - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2013 ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of incorporation) (Com |
|
| July 30, 2013 |
EX-99.1 Exhibit 99.1 NEWS RELEASE—for immediate release Alexza Pharmaceuticals Announces European Launch of ADASUVE® (Staccato® Loxapine) Alexza’s Partner Ferrer Records First Product Sales in Germany Mountain View, California—July 30, 2013 - Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced that the company’s commercial partner Grupo Ferrer Internacional, S.A. has initiated sales of ADA |
|
| May 31, 2013 |
As filed with the Securities and Exchange Commission on May 31, 2013 Registration No. |
|
| May 23, 2013 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2013 ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of incorporation) (Commissi |
|
| May 23, 2013 |
ALEXZA PHARMACEUTICALS, INC. 1,437,481 SHARES OF COMMON STOCK 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. |
|
| May 22, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) ALEXZA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 015384100 (CUSIP Number) April 22, 2013 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| May 22, 2013 |
ALEXZA PHARMACEUTICALS, INC. 2005 NON-EMPLOYEE DIRECTORS’ STOCK OPTION PLAN EX-10.2 Exhibit 10.2 ALEXZA PHARMACEUTICALS, INC. 2005 NON-EMPLOYEE DIRECTORS’ STOCK OPTION PLAN 1. GENERAL. (a) Eligible Option Recipients. The persons eligible to receive Options are the Non-Employee Directors of the Company. (b) General Purpose. The Company, by means of the Plan, seeks to retain the services of its Non-Employee Directors, to secure and retain the services of new Non-Employee Di |
|
| May 22, 2013 |
ALEXZA PHARMACEUTICALS, INC. 2005 EQUITY INCENTIVE PLAN EX-10.1 Exhibit 10.1 ALEXZA PHARMACEUTICALS, INC. 2005 EQUITY INCENTIVE PLAN 1. GENERAL. (a) Eligible Stock Award Recipients. The persons eligible to receive Stock Awards are Employees, Directors and Consultants. (b) Available Stock Awards. The Plan provides for the grant of the following Stock Awards: (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Stock Purchase Awards, (iv) |
|
| May 22, 2013 |
FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2013 (May 21, 2013) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction (Co |
|
| May 14, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2013 ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of incorporation) |
|
| May 14, 2013 |
EX-99.1 Exhibit 99.1 NEWS RELEASE - for immediate release Alexza Reports 2013 First Quarter Financial Results Management to Review Results and Provide Business Update in Conference Call Scheduled Today for 5:00 p.m. Eastern Time Mountain View, California - May 14, 2013 - Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the fiscal quarter March 31, 2013. The net loss |
|
| May 8, 2013 |
EX-99.1 Exhibit 99.1 NEWS RELEASE - for immediate release Teva and Alexza Announce Teva’s License to Market ADASUVE® in the U.S. Adasuve® (loxapine) inhalation powder is approved in the U.S. for the acute treatment of agitation associated with schizophrenia and bipolar disorder North Wales, PA & Mountain View, CA - May 8, 2013 - Teva Pharmaceuticals USA, Inc., a subsidiary of Teva Pharmaceutical I |
|
| May 8, 2013 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2013 (May 7, 2013) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of incorpo |
|
| May 8, 2013 |
EX-99.2 Exhibit 99.2 NEWS RELEASE - for immediate release Alexza Announces Conference Call to Discuss Agreement with Teva to Market ADASUVE® in the U.S. Call Scheduled Today for 9:00 a.m. Eastern Time Mountain View, California, May 8, 2013 - Alexza Pharmaceuticals, Inc. (NASDAQ: ALXA) announced today that they have entered into an exclusive U.S. license and supply agreement with Teva Pharmaceutica |
|
| May 7, 2013 |
ALEXZA PHARMACEUTICALS, INC. Common Stock Prospectus Supplement No. 4 (to Prospectus dated April 23, 2010) Filed Pursuant to Rule 424(b)(3) Registration No. 333-162582 ALEXZA PHARMACEUTICALS, INC. Common Stock This Prospectus Supplement No. 4 supplements and amends the prospectus dated April 23, 2010 (the “Prospectus”), as supplemented and amended by that certain Prospectus Supplement No. 1 dated October 26, 2010, that certain Prospectus |
|
| April 11, 2013 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, fo |
|
| April 10, 2013 |
Definitive Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 3, 2013 |
Form 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2013 (March 29, 2013) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdict |
|
| April 2, 2013 |
ALEXZA PHARMACEUTICALS, INC. 2013 CASH BONUS PLAN EX-10.1 Exhibit 10.1 ALEXZA PHARMACEUTICALS, INC. 2013 CASH BONUS PLAN 1. GENERAL. (a) Eligible Bonus Award Recipients. The persons eligible to receive Bonus Awards are all Alexza employees, including Officers, Executive Directors, Directors, Managers and Individual Contributors. (b) Form of Bonus Awards. All Bonus Awards under the Bonus Plan will be paid in cash. (c) Purpose. The Company, by mean |
|
| April 2, 2013 |
8-K 1 d515659d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2013 (March 29, 2013) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State o |
|
| March 26, 2013 |
Alexza Reports 2012 Fourth Quarter and Full Year Financial Results EX-99.1 Exhibit 99.1 NEWS RELEASE - for immediate release Alexza Reports 2012 Fourth Quarter and Full Year Financial Results Management to Review Results and Provide Business Updates in Conference Call Scheduled Today for 5:00 p.m. Eastern Time Mountain View, California - March 26, 2013 - Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the fiscal quarter and full y |
|
| March 26, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2013 ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of incorporation) (Commis |
|
| March 13, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2013 (March 12, 2013) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction |
|
| March 13, 2013 |
EX-99.1 Exhibit 99.1 NEWS RELEASE - for immediate release Peter W. Schineller Joins Alexza Pharmaceuticals as Senior Vice President and Chief Commercial Officer Mountain View, California, March 13, 2013 - Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that Peter W. Schineller has joined the company as Senior Vice President and Chief Commercial Officer. Mr. Schineller brings more than |
|
| February 21, 2013 |
Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2013 ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdiction of incorporat |
|
| February 21, 2013 |
Alexza Receives Marketing Authorization for ADASUVE® (Staccato® Loxapine) in the European Union EX-99.1 Exhibit 99.1 NEWS RELEASE - for immediate release Alexza Receives Marketing Authorization for ADASUVE® (Staccato® Loxapine) in the European Union Mountain View, California and Barcelona, Spain - February 21, 2013 - Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) and Grupo Ferrer Internacional, S.A., today announced that the European Commission has granted marketing authorization for ADASUVE (S |
|
| February 14, 2013 |
ALXA / Alexza Pharmaceuticals, Inc. / CREDIT SUISSE AG/ - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Alexza Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 015384100 (CUSIP Number) Calendar Year 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| February 14, 2013 |
ALXA / Alexza Pharmaceuticals, Inc. / LANSDOWNE PARTNERS AUSTRIA GMBH Passive Investment SC 13G/A 1 d135658513g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No. 2 ALEXZA PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of Securities) 015384209 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| February 14, 2013 |
ALXA / Alexza Pharmaceuticals, Inc. / CREDIT SUISSE - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Alexza Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 015384100 (CUSIP Number) Calendar Year 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| February 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* ALEXZA PHARMACEUTICALS INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 015384209 (CUSIP Number) December 26, 2012 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| February 14, 2013 |
In accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998), this Statement is being filed by Credit Suisse AG (the "Bank"), a Swiss bank, on behalf of its subsidiaries to the extent that they constitute the Investment Banking Division (the "Investment Banking Division") and the Alternative Investments business (the "AI Business") and U.S. private client services |
|
| February 14, 2013 |
ALXA / Alexza Pharmaceuticals, Inc. / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 1 Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Alexza Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 015384209 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule |
|
| February 14, 2013 |
In accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998), this Statement is being filed by Credit Suisse AG (the "Bank"), a Swiss bank, on behalf of its subsidiaries to the extent that they constitute the Private Banking and Wealth Management Division other than the Alternative Investments business (the "AI Business") and U.S. private client services business ( |
|
| February 13, 2013 |
EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G, dated February 27, 2012, with respect to the shares of Alexza Pharmaceuticals, Inc. Common Stock, par value $0.0001 per share, is, and any amendments thereto executed by each of us shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) und |
|
| February 13, 2013 |
ALXA / Alexza Pharmaceuticals, Inc. / Boxer Capital, LLC - SC 13G/A Passive Investment SC 13G/A 1 d483146dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ALEXZA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 015384100 (CUSIP Number) December 31, 2012 (Date of Event which Requires Filing of this Statement) Check t |
|
| February 12, 2013 |
ALXA / Alexza Pharmaceuticals, Inc. / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Expires: January 31, 2006 Estimated average burden hours per response . |
|
| February 8, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2013 (February 7, 2013) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdic |
|
| January 28, 2013 |
AMENDMENT NO. 2 TO THE ALEXZA PHARMACEUTICALS, INC. 2005 NON-EMPLOYEE DIRECTORS’ STOCK OPTION PLAN Amendment to 2005 Non-Employee Directors' Stock Option Plan Exhibit 99.4 AMENDMENT NO. 2 TO THE ALEXZA PHARMACEUTICALS, INC. 2005 NON-EMPLOYEE DIRECTORS’ STOCK OPTION PLAN Effective January 2, 2013, the Board of Directors of Alexza Pharmaceuticals, Inc. (the “Company”) adopted an amendment to the Company’s 2005 Non-Employee Directors’ Stock Option Plan (the “Plan”) so that Section 6(a) of the Plan |
|
| January 28, 2013 |
Form S-8 As filed with the Securities and Exchange Commission on January 28, 2013 Registration No. |
|
| January 3, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2013 (January 2, 2013) ALEXZA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-51820 77-0567768 (State or other jurisdicti |
